A Comparative Analysis of Clinical Outcomes Between Conversion to MTOR Inhibitor and Calcineurin Inhibitor Reduction in Managing BK Viremia Among Kidney Transplant Patients

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 4

PMID 38834615

Authors

Ara Cho

Sunghae Park

Ahram Han

Jongwon Ha

Jae Berm Park

Kyo Won Lee

Sangil Min

Affiliations

Soon will be listed here.

Abstract

BK virus-associated nephropathy (BKVAN) exerts a substantial impact on allograft survival, however, the absence of robust clinical evidence regarding treatment protocols adds to the complexity of managing this condition. This study aimed to compare the two treatment approaches. The study population consisted of patients who underwent kidney transplantation between January 2016 and June 2020 at two tertiary hospitals in Korea. Patients diagnosed with BK viremia were evaluated based on their initial viral load and the treatment methods. The 'Reduction group' involved dose reduction of tacrolimus while the 'Conversion group' included tacrolimus discontinuation and conversion to sirolimus. A total of 175 patients with an initial viral load (iVL) ≥ 3 on the log10 scale were evaluated within two iVL intervals (3-4 and 4-5). In the iVL 4-5 interval, the Reduction group showed potential effectiveness in terms of viral clearance without statistically significant differences. However, within the iVL 3-4 interval, the Reduction group demonstrated superior viral clearance and a lower incidence of biopsy-proven acute rejection (BPAR) than the Conversion group. The renal function over 12 months after BKV diagnosis showed no statistically significant difference. Reducing tacrolimus compared to converting to mTORi would be a more appropriate treatment approach for BK viral clearance in kidney transplantation. Further research is warranted in a large cohort of patients.

References

Mallat S, Tanios B, Itani H, Lotfi T, McMullan C, Gabardi S . CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol. 2017; 12(8):1321-1336. PMC: 5544521. DOI: 10.2215/CJN.13221216. View

Kable K, Davies C, OConnell P, Chapman J, Nankivell B . Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin. Transplant Direct. 2017; 3(4):e142. PMC: 5381735. DOI: 10.1097/TXD.0000000000000641. View

Ando S, Perkins C, Sajiki Y, Chastain C, Valanparambil R, Wieland A . mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. J Clin Invest. 2022; 133(2). PMC: 9843061. DOI: 10.1172/JCI160025. View

Shen C, Wu B, Lien T, Yang A, Yang C . BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses. 2021; 13(3). PMC: 7998398. DOI: 10.3390/v13030487. View

Hirsch H, Yakhontova K, Lu M, Manzetti J . BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. Am J Transplant. 2015; 16(3):821-32. PMC: 5064607. DOI: 10.1111/ajt.13541. View

Hirsch H, Steiger J . Polyomavirus BK. Lancet Infect Dis. 2003; 3(10):611-23. DOI: 10.1016/s1473-3099(03)00770-9. View

Hirsch H, Randhawa P . BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13528. DOI: 10.1111/ctr.13528. View

Ginevri F, Azzi A, Hirsch H, Basso S, Fontana I, Cioni M . Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant. 2007; 7(12):2727-35. DOI: 10.1111/j.1600-6143.2007.01984.x. View

Dharnidharka V, Cherikh W, Abbott K . An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009; 87(7):1019-26. DOI: 10.1097/TP.0b013e31819cc383. View

10.

Benavides C, Pollard V, Mauiyyedi S, Podder H, Knight R, Kahan B . BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation. 2007; 84(1):83-8. DOI: 10.1097/01.tp.0000268524.27506.39. View

11.

Dall A, Hariharan S . BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol. 2008; 3 Suppl 2:S68-75. PMC: 3152275. DOI: 10.2215/CJN.02770707. View

12.

Bischof N, Hirsch H, Wehmeier C, Amico P, Dickenmann M, Hirt-Minkowski P . Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant. 2018; 34(7):1240-1250. DOI: 10.1093/ndt/gfy346. View

13.

Gardner S, Field A, Coleman D, HULME B . New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet. 1971; 1(7712):1253-7. DOI: 10.1016/s0140-6736(71)91776-4. View

14.

Brennan D, Agha I, Bohl D, Schnitzler M, Hardinger K, Lockwood M . Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005; 5(3):582-94. DOI: 10.1111/j.1600-6143.2005.00742.x. View

15.

Vela C, Jouve T, Chevallier E, Imerzoukene F, Germi R, Le Marechal M . Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study. J Clin Med. 2022; 11(24). PMC: 9785214. DOI: 10.3390/jcm11247292. View

16.

Wali R, Drachenberg C, Hirsch H, Papadimitriou J, Nahar A, Mohanlal V . BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation. 2004; 78(7):1069-73. DOI: 10.1097/01.tp.0000142127.84497.50. View

17.

Moscarelli L, Caroti L, Antognoli G, Zanazzi M, Di Maria L, Carta P . Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant. 2013; 27(4):546-54. DOI: 10.1111/ctr.12151. View

18.

Schaub S, Hirsch H, Dickenmann M, Steiger J, Mihatsch M, Hopfer H . Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant. 2010; 10(12):2615-23. DOI: 10.1111/j.1600-6143.2010.03310.x. View

19.

Tedesco Silva Jr H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C . Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010; 10(6):1401-13. DOI: 10.1111/j.1600-6143.2010.03129.x. View

20.

Araki K, Turner A, Shaffer V, Gangappa S, Keller S, Bachmann M . mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. PMC: 2710807. DOI: 10.1038/nature08155. View